3C Patch
Commercial- Indications
- Diabetic foot ulcers
Company intelligence / Profile preview
Reapplix
Birkerød, Capital Region of Denmark, Denmarkreapplix.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Commercial
01
Overview
Reapplix has developed the evidence-based, autologous biological wound therapy system called the 3C Patch®, which uses only a patient’s own blood to create a patch applied directly to chronic wounds such as diabetic foot ulcers. The company’s technology has demonstrated positive results in large randomized controlled trials and received coding/reimbursement approval in the US. The company is currently commercializing its product in the US and select European markets.
- Therapeutic areas
- EndocrinologyDermatology
- Modalities
- DeviceBiologic (autologous blood-derived patch)Regenerative medicine therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Reapplix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reapplix.